Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · IRulya Therapeutics Inc. (IRLA)

IRulya Therapeutics holders approve share increase and Series C preferred conversion

Mixed Impact 4 of 5 shareholder Written later

At a special meeting on October 6, 2026, stockholders approved raising authorized common stock from 250,000,000 to 275,000,000 shares and approved issuing common stock on conversion of Series C preferred stock and warrants, which the filing says could exceed 20% of outstanding shares and may, with management and board changes, result in a change of control. The filing body names Quince Therapeutics, Inc. while the header lists IRulya Therapeutics Inc., so the registrant identity should be confirmed. For shareholders, the approvals add capacity for potential dilution and a possible change in control.

Key points

  • Authorized common stock increased from 250,000,000 to 275,000,000 shares, effective October 6, 2026
  • Proposal 2 passed with 343,517 votes for and 5,759 against; Proposal 1 passed with 180,550 votes for and 5,742 against
  • Proposal 1 may result in a change of control under Nasdaq Listing Rule 5635(b)
  • 2026 Equity Incentive Plan reserve starts at 821,872 shares; 2026 ESPP reserve starts at 142,045 shares

The filing

CompanyIRulya Therapeutics Inc. (IRLA)
Form8-K, current report
Filed with the SECOct 6, 2026, 4:57 PM ET
Accession number0001193125-26-415730

Items reported: 5.02 Director / Officer Change5.03 Bylaw / Charter Amendment5.07 Shareholder Vote Results

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.